^
Association details:
| Biomarker: | VEGFD elevation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
Published date:
03/01/2018
Excerpt:
Evaluation of the combined ME + MC populations found that the median OS in the ramucirumab + FOLFIRI arm compared with placebo + FOLFIRI showed an improvement of 2.4 months in the high VEGF-D subgroup [13.9 months...versus 11.5 months..., respectively], and a decrease of 0.5 month in the low VEGF-D subgroup [12.6 months...versus 13.1 months..., respectively]....The RAISE biomarker program identified VEGF-D as a potential predictive biomarker for ramucirumab efficacy in second-line mCRC.
Secondary therapy:
FOLFIRI
DOI:
10.1093/annonc/mdx767
Trial ID:
